GlassScriptPhysician profile
David Michel Sabbagh
NPI 1295183747
$4,292.23
in general payments reported to CMS, 2019-2025
34 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $465 · 2021: $544 · 2022: $944 · 2023: $416 · 2024: $581 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.10 | 2021-2025 | |
| Novo Nordisk INC | $389.62 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $371.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $315.10 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $293.87 | 2024-2025 | Fanapt |
| Radius Health, INC. | $252.48 | 2020-2025 | Tymlos |
| Alkermes, INC. | $235.83 | 2021-2025 | Lybalvi, Aristada |
| Lilly USA, LLC | $234.81 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $217.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $157.02 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $155.83 | 2022-2025 | Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.00 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $119.25 | 2024-2025 | Auvelity, Sunosi |
| Glaxosmithkline, LLC. | $113.07 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $100.45 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $94.71 | 2022-2025 | Rexulti |
| Pfizer INC. | $91.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.61 | 2022-2024 | Spiriva Respimat, Jardiance |
| Janssen Pharmaceuticals, INC | $59.71 | 2021-2023 | Spravato |
| Exact Sciences Corporation | $57.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $50.96 | 2022-2025 | Nuzyra |
| Noven Therapeutics, LLC | $41.46 | 2025 | Xelstrym |
| Abbott Laboratories | $36.24 | 2022-2025 | Freestyle Libre 3 |
| Bardy Diagnostics, INC. | $35.96 | 2021-2022 | |
| Astellas Pharma US INC | $30.65 | 2019-2023 | Veozah |
| Mylan Specialty L.P. | $20.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.25 | 2025 | Xifaxan |
| Medtronic, INC. | $17.71 | 2023 | Interstim |
| Dexcom, INC. | $16.54 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $16.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sabbagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.